Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Stifel 2023 Healthcare Conference, taking place in New York, NY.

Management is scheduled to present on Tuesday, November 14, 2023 from 4:45pm to 5:15pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Philip Taylor Gilmartin Group 415-937-5406 Investors@senseonics.com

Senseonics (AMEX:SENS)
Graphique Historique de l'Action
De Jan 2024 à Fév 2024 Plus de graphiques de la Bourse Senseonics
Senseonics (AMEX:SENS)
Graphique Historique de l'Action
De Fév 2023 à Fév 2024 Plus de graphiques de la Bourse Senseonics